Antibody Drug Conjugates — An Emerging Class of Cancer Therapeutics Which Pose Risks to the Corneal and Anterior Segment Health

Enroll Now


CME Activity Pricing

ASCRS Member Price: FREE
Nonmember Price:  FREE

Description

This activity will cover what Antibody Drug Conjugates are, what common diseases we see them used for, and anterior segment complications/adverse reactions.

Credits: By completing this activity you will earn 1.5 AMA PRA Category 1 Credits™.
Duration: 90 minutes
Activity Expiration Date: March 31, 2026

Faculty

Winston Chamberlain, MD Asim Farooq, MD Stella Kim, MD Naveen Rao, MD Kamran Riaz, MD

Learning Objectives

Ophthalmologists attending this program should be able to:

  • Discuss what Antibody Drug Conjugates are and what common diseases we see them used for.
  • Review the anterior segment complications/adverse reactions to ADC’s.
  • Analyze how anterior segment surgeons monitor and evaluate complications.
  • Compare options physicians have for treatment of side effects.
  • Demonstrate a communication algorithm with the oncologist including considerations for dose or frequency changes.


Enroll Now